Dyslipidemia and diabetes

Citoxlab – Your one-stop CRO for preclinical research

> Radiation safety and efficacy studies

> Osteoporosis / Bone safety and efficacy models

> Dyslipidemia and diabetes

Diabetes is associated with a high risk of cardiovascular disease, which is the primary cause of death in the diabetic population. Dyslipidemia, which is characterized by an abnormal amount of lipids in the blood, is increasingly observed not only in the industrialized world but also in developing countries.

When associated with diabetes, dyslipidemia becomes one of the key risk factors for cardiovascular disease, leading to morbidity and mortality. There is a worldwide increase in the incidence of diabetic dyslipidemia, with a prediction that figures could almost double over the next ten years.  Management of diabetic dyslipidemia is a key element in the multifactorial approach for the prevention of cardiovascular diseases.

Citoxlab offers evaluation of new drug candidates to assess therapeutic potential. Recognized translational diabetic (DI), dyslipidemia (DY) or diabetic dyslipidemia (DD) models (rodents and non‑rodents) are used :

  • Chemically-induced diabetes
  • Surgically-induced diabetes
  • Diet-induced diabetes
  • Diet-induced dyslipidemia
  • Selective breeding
  • Transgenic models
  • Combined diabetic dyslipidemia

 Technologies used to support these investigations :

  • Hematology (ADVIA 120)
  • Blood biochemistry (ADVIA 1650)
  • Urine analysis (10-Multistix SG test strips/Clinitek 500)
  • Glucose and/or insulin tolerance tests
  • Evaluation of renal function
  • Evaluation of cardiovascular function using implanted telemetry or Jacketed External Telemetry (JET)
  • Evaluation of effect on whole body composition using Dual-Energy X-Ray Absorptiometry (DEXA)
  • Ophthalmology
  • Histopathology
  • Immunohistopathology